POPCaP Authorization Act of 2026
- Sponsor
- Rep. Murphy, Gregory F. [R-NC-3]
- Committees
- Veterans' Affairs Committee (primary)
- Last action
- Jun 12, 2026
Bottom line
The bill establishes a structured, nationwide precision oncology program within the VA to enhance personalized treatment and research for veterans with prostate and related genitourinary cancers.
What it actually does
This bill directs the Secretary of Veterans Affairs to establish a comprehensive precision oncology program for prostate and non-prostate genitourinary cancers within the Department of Veterans Affairs. It mandates the designation of at least 21 Centers of Excellence across all Veterans Integrated Service Networks, establishes a Program Leadership team to coordinate research and clinical trials, and authorizes specific funding for the program's initial years. The program aims to provide advanced, personalized cancer care to eligible veterans through genetic sequencing, biomarker-specific clinical trials, and a centralized data registry.
Proponents argue
Proponents argue that this program will significantly advance cancer care for veterans by leveraging cutting-edge precision oncology techniques, leading to more effective, personalized treatments and improved survival rates. They emphasize the importance of a coordinated national effort, data sharing, and dedicated research to address the specific needs of the veteran population, particularly for a prevalent cancer like prostate cancer.
Opponents contend
Critics might raise concerns about the administrative complexity and potential costs associated with establishing and maintaining such a specialized program across numerous facilities. They could argue that resources might be better allocated to broader cancer care initiatives or that the program's benefits might not reach all veterans equitably, especially those in rural or underserved areas, despite the intent to extend resources to affiliated medical centers.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its core provisions within a reasonable timeframe.
Section 2(a), new 38 U.S.C. 7330E(a)
Establishment of Precision Oncology Program for Cancer of the Prostate (POPCaP)
This provision directs the Secretary of Veterans Affairs to establish a precision oncology program specifically for prostate cancer, referred to as the 'Program.' It outlines that the Secretary must designate Centers of Excellence and maintain a Program Leadership team to carry out the program's objectives. This is the foundational element of the bill, creating the new program within the VA's healthcare system.
Supporters argue
Supporters contend that establishing a dedicated program ensures a focused and coordinated approach to tackling prostate cancer, a significant health concern for veterans, by integrating advanced precision medicine into VA care.
Critics contend
No specific opposition is typically raised against the general establishment of a program aimed at improving veteran health, though concerns about resource allocation or scope might be debated.
Tradeoffs
The tradeoff involves dedicating specific resources to prostate cancer precision oncology, potentially at the expense of other VA health initiatives, versus the potential for significant advancements in treating this specific disease.
Section 2(a), new 38 U.S.C. 7330E(b)
Eligibility for Program Enrollment
This section defines who is eligible to receive additional medical services through the new Program. To be eligible, a veteran must be enrolled in the VA's patient enrollment system (under section 1705 of title 38) and have a diagnosis of prostate cancer or non-prostate genitourinary cancer. This broadens the scope beyond just prostate cancer to include other related cancers.
Section 2(a), new 38 U.S.C. 7330E(c)
Requirements for Centers of Excellence
This provision details the mandatory activities and staffing for each designated Center of Excellence. Activities include genetic sequencing, implementing a uniform sequencing platform, participating in a Telemedicine Tumor Board and a prostate cancer registry, providing travel support for studies, developing biomarker-specific clinical trials, and engaging in industry-sponsored studies. Each Center must also employ a multidisciplinary team including oncologists, radiologists, urologists, pathologists, and research staff.
Section 2(a), new 38 U.S.C. 7330E(d)
Designation of Centers of Excellence
This section mandates that the Secretary of Veterans Affairs must designate not fewer than 21 medical facilities as Centers of Excellence, ensuring at least one in each Veterans Integrated Service Network (VISN). It also specifies that at least seven of these Centers must have a genitourinary program. The bill explicitly lists 28 initial medical facilities that are designated as Centers of Excellence upon enactment, ensuring immediate operational capacity.
Section 2(a), new 38 U.S.C. 7330E(g)
Program Leadership Team Establishment and Responsibilities
This provision establishes a Program Leadership team, initially located at the Seattle VA Medical Center, which is guaranteed COE status until at least 2033. The team must include an Executive Director, Clinical Director, and Research Director, who are VA employees. Their responsibilities include strategic liaison with clinical trial sponsors, coordinating participation in National Cancer Institute studies, facilitating study development, creating a model for hybrid decentralized clinical trials, maintaining a public prostate cancer registry, and developing a uniform genetic sequencing platform for all Centers of Excellence.
Section 2(a), new 38 U.S.C. 7330E(i)
Authorization of Appropriations
This section authorizes the appropriation of $15,500,000 for each of fiscal years 2027, 2028, and 2029 to the Secretary of Veterans Affairs specifically for carrying out the Precision Oncology Program for Cancer of the Prostate. This provides the initial funding mechanism for the program's establishment and early operations.
Section 2(c) of the Act
Protection of Existing Centers of Excellence Functions and Funding
This provision, separate from the new U.S. Code section, states that the Secretary of Veterans Affairs may not remove any staff, program, or function relating to prostate cancer from existing Centers of Excellence (designated under section 7330D of title 38) that were in effect on January 1, 2023, until January 1, 2030. Furthermore, funding provided to these existing Centers from public and private sources as of January 1, 2023, cannot be reduced until January 1, 2030.
This section prevents the VA from removing staff, programs, or functions related to prostate cancer from existing Centers of Excellence (under 38 U.S.C. 7330D) or reducing their funding below 2023 levels until January 1, 2030.
Section 2(c) of the Act
Why it matters:This is standard legislative practice for transitional provisions or those affecting existing law outside the direct scope of the new codified section. It's likely intended to provide a 'hold harmless' period for existing programs as the new, broader program is rolled out.
Case for: Supporters would argue this provision is crucial for ensuring stability and continuity of care for veterans currently benefiting from existing prostate cancer programs. It prevents any immediate negative impacts or resource shifts during the establishment of the new, larger precision oncology program.
Case against: No strong case against this provision exists, as it aims to protect current services. However, some might argue that it could limit the VA's flexibility to strategically reallocate resources to the new program if it proves more effective or efficient, potentially creating redundant efforts in the short term.
Estimated impact: Maintains current staffing, programs, and funding levels for an unspecified number of existing VA Centers of Excellence focused on prostate cancer for approximately four years.